Background:Hypoglycaemia accounts for approximately one tenth of term
Results: There were 474 admissions for hypoglycaemia (17.8% of total admissions).
Their median (IQR) blood glucose on admission was 2.1 (1.7-2.4) mmol/L, gestation at delivery 38.1 (36.7-39.3) weeks, birthweight percentile 31.4 (5.4-68.9), their length of stay was 3.0 (2.0-5.0). Admissions equated to a total of 2107 hospital days. The total cost of stay was 1,316,591 GBP. The antenatal factors associated with admission for hypoglycaemia were maternal hypertension (19.8%), maternal diabetes (24.5%), FGR (25.9%) and pathological intrapartum cardiotocograph (23.4%). In 13.7% of cases there was no associated pregnancy complication.
Multivariate logistic regression analysis demonstrated lower gestational age, z-score birthweight squared, exclusive breastfeeding and maternal prescribed nifedipine were independently associated with the length and cost of stay. 
Conclusions
The aims of this study were to determine the prevalence of admissions for hypoglycaemia in late preterm and term infants to a tertiary neonatal unit, to report the length and cost of those admissions and identify independent antenatal and perinatal predictors of the length and cost of stay.
Materials and Methods

Study design
A retrospective audit of admissions between 1/1/2012 and 31/12/2015 of infants born after 35 weeks of gestational age with hypoglycaemia to the neonatal unit at King's College Hospital NHS Foundation Trust (KCH), London was performed. Infants with a birth weight of <1.8 kg or a gestational age <34 completed weeks were routinely admitted to the neonatal unit, irrespective of blood sugar homeostasis and were excluded from this study. The study was registered as an audit with the Clinical Governance Department of KCH.
On admission to the neonatal unit, the infant's symptoms, temperature and blood glucose levels were recorded. Subsequently, the following information was collected from the maternal and neonatal medical notes: maternal antenatal diabetes Screening for gestational diabetes (GDM) was according to local protocols.
Definitions of maternal, antenatal and labour outcomes
Maternal hypertension was defined as a systolic or diastolic blood pressure 
Definition of hypoglycaemia and measuring devices
A blood glucose level below 2.6 mmol/L was used to define neonatal hypoglycaemia.
[23] The blood glucose measurement in the postnatal ward and in the neonatal unit was undertaken by whole blood analysis using hand held glucometers (Ascensia Contour blood glucose meter, Bayer Healthcare LLC, PA, USA) which underwent a two-point calibration on a daily basis.
Management of hypoglycaemia
The management of infants at risk of hypoglycaemia in the postnatal ward and after admission to the neonatal unit was in accordance with national guidelines. The maternal/antenatal, labour, neonatal and admission data of the admitted infants are presented in Table 1 . One hundred and sixteen mothers had diabetes (24.5%), 94 had hypertension (19.8%), 69 had pyrexia>38 0 C in labour (14.6%), 123 of the infants had FGR (25.9%) and 111 (23.4%) had a pathological CTG prior to delivery (Table 1, Figure 1 ). There was an overlap of pathologies in 18.8% of cases, whilst in 13.7% there was no associated pregnancy complication.
The cumulative length of stay of the admitted infants was 2,107 days, of which 960 days were in the high dependency care (HDU). Fifty-six percent of the admitted infants were discharged by day three of stay, 85% were discharged by day 7 of stay and 90% were discharged by day 10 of stay ( Figure 2 ). The cumulative cost of stay of the admitted infants was 1,316,591 GBP (329,148 GBP per year), of which 842,880 GBP related to high dependency costs.
Univariate regression analysis
The length and cost of stay were significantly associated with: history of maternal diabetes, maternal use of Nifedipine, FGR, maternal administration of antibiotics in labour, pathological CTG, gestational age at delivery, square ofthe birth weight z-score, age on admission, admission blood sugar and exclusive breastfeeding ( Table 2 ).
There was no association between length or cost of stay and: neonatal symptoms, admission temperature, delivery by caesarean section, maternal pyrexia in labour >38 0 C, Apgar score at 5 minutes<7, gender, singleton birth, maternal hypertension or other medical conditions, maternal treatment with labetalol or methyldopa (data not presented).
Multivariate regression analysis
Multivariate regression analysis demonstrated that greater length of admission (R 2 = 0.13, p<0.0001) and cost of admission (R 2 = 0.14, p<0.0001) were independently associated with lower gestational age and blood glucose level on admission, (table 3) .
Age of admission, maternal administration of antibiotics in labour, maternal diabetes and FGR were not independent predictors of length or cost of stay (data not presented).
Discussion
We have demonstrated that hypoglycaemia after 35 weeks accounts for nearly one fifth of neonatal admissions, costing approximately 1.3 million GBP over a four year period in one tertiary NICU. Lower gestational age and admission blood glucose, low and high z-score birthweight, maternal nifedipine and exclusive breastfeeding were associated with longer duration of stay.
To our knowledge this is the first study to examine the association of maternal disease and intrapartum events with the morbidity related to neonatal hypoglycaemia as assessed by the length and cost of admission.
The prevalence of admissions for hypoglycaemia in our unit, however, was higher than previously reported. In a recent national report, the prevalence of admissions for hypoglycaemia was 10% for term admissions, [2] whilst in our study this was 23.3%. In our population, 86% of those with a prolonged admission had pre-existing maternal medical disease (hypertension or diabetes), maternal antihypertensive treatment, FGR or intrapartum complications (maternal antibiotics in labour, pathological CTG). It is, therefore, possible that the reported 10% national rate is not uniform across all units, but varies according to the prevalence of maternal risk factors in local populations.
Our study highlights that the severity of neonatal hypoglycaemia may be the result of Interestingly, in our cohort, maternal use of nifedipine rather than labetalol was associated with prolonged stay and increased cost. The evidence for labetalol as a cause for neonatal hypoglycaemia, however, is conflicted. Some epidemiological studies have reported an association after controlling a small number of confounders [10] whilst others argue that it is the fetal growth restriction, secondary to the placental insufficiency, which causes the need for treatment and is responsible for the neonatal hypoglycaemia.
[15] Our results showing that nifedipine was associated with longer stay and higher cost likely reflects our practice in the choice of antihypertensive agents in pregnancy. We have previously developed a prediction model for the response to labetalol treatment in pregnancy by using maternal demographic and central haemodynamic data.
[29] Women with low cardiac output-high resistance are more likely to respond to a vasodilator, such as nifedipine.
Such pregnancies, are associated with established or impending fetal growth restriction as the vasoconstriction is a compensatory mechanism for the reduced intravascular space.[30, 31] It is therefore, likely that in our multivariate model Nifedipine is a proxy for fetal growth restriction.
The increased risk of hypoglycaemia in late preterm infants is the result of immature hepatic glycogenolysis and gluconeogenesis and limited enteral intake due to gastrointestinal immaturity and poor suck-swallow coordination.
[32] In agreement with the above, our study identified low gestational age as an independent predictor J U S T A C C E P T E D of admission for hypoglycaemia in infants more than 35 weeks of gestation. In our study, exclusive breastfeeding was also identified as an independent predictor of admission for neonatal hypoglycaemia. Early breastfeeding support increases the likelihood of successful breastfeeding and milk production. For both public health and economic benefit, i.e. promotion of successful breastfeeding and avoidance of neonatal admissions, it could be argued that focusing of intensive early support for breastfeeding in this high risk group should be prioritised. [33] We acknowledge as a limitation that this was a retrospective study that focused on the characteristics of the admitted infants and did not explore that management in the postnatal ward. Nevertheless, our study group represents the most severe end of the spectrum of hypoglycaemia with regard to morbidity and cost. 
